Company news

DiaMedica Therapeutics Inc. news in 2026

DiaMedica Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026

November 5, 2026

DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

October 22, 2026

DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

October 19, 2026

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

September 30, 2026

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

September 2, 2026

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 10, 2026

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

August 4, 2026

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

June 23, 2026

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

June 16, 2026

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

May 27, 2026

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

May 20, 2026

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 12, 2026

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 6, 2026

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

April 30, 2026

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

March 29, 2026

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

March 22, 2026

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

March 4, 2026

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

February 23, 2026

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

January 19, 2026

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Calls in 2026

Decks in 2026